David S. Friedman

Dr. Friedman’s research has focused on angle closure glaucoma, ophthalmic epidemiology, and glaucoma therapy with an emphasis on medication adherence among glaucoma patients.  Dr. Friedman has published nearly 300 peer-reviewed articles.  He currently leads a CDC-funded program to identify novel approaches to screen underserved populations for eye diseases, especially glaucoma.

Dr. Friedman is world renowned for his contributions to the study of the mechanisms, epidemiology, and prevention of angle-closure glaucoma.  Over the last 20 years he has worked closely with researchers in Singapore, Guangzhou, Beijing, and south India on this research.  He identified novel dynamic risk factors for angle closure.  This work formed the foundation for two seminal studies of angle closure glaucoma treatment including the EAGLE Trial and the Zhongshan Angle Closure Prevention (ZAP) Study, both of which were published in Lancet.  Dr. Friedman is a member of the Glaucoma Research Society (limited to the 100 leading glaucoma researchers) and the Alcon Research Institute (composed of the top 6 researchers in ophthalmology each year).

Dr. Friedman is the Director of the Glaucoma Service, who specializes in treating all forms of glaucoma except for pediatric patients. He has pursued excellence in clinical care, research, and education, and is considered a leader in all three fields. As a clinician he has consistently been elected a “Best Doctor” and frequently is asked to lecture both domestically and internationally on glaucoma care. He is world renowned for the treatment of angle closure glaucoma. He performs a wide range of glaucoma procedures as well as cataract surgery.

Dr. Friedman’s research focuses on angle closure glaucoma, ophthalmic epidemiology, and glaucoma therapy with an emphasis on medication adherence among glaucoma patients. Dr. Friedman has published nearly 300 peer-reviewed articles.